A particle arrangement transportation device includes: a base material in which is formed a flow channel from an inlet port-side opening through which a solution containing particles to be an object of arrangement and transportation is introduced to an outlet port-side opening; an electrode which is formed along the flow channel on a wall surface of the base material being exposed in the flow channel; electrodes which are formed along the flow channel in the base material on both sides of the flow channel; and a power supply which applies an AC voltage between the electrodes.

A particle arrangement transportation device includes: a base material in which is formed a flow channel from an inlet port-side opening through which a solution containing particles to be an object of arrangement and transportation is introduced to an outlet port-side opening; an electrode which is formed along the flow channel on a wall surface of the base material being exposed in the flow channel; electrodes which are formed along the flow channel in the base material on both sides of the flow channel; and a power supply which applies an AC voltage between the electrodes.

In order to quantitatively characterize biological objects, for example individual cells, a stimulus is applied to a biological object (8) in a contactless fashion. A measurement and a further measurement are performed on the biological object (8) in order to ascertain a response of the biological object (8) to the stimulus, wherein the measurement and the further measurement comprise detecting Raman scattering on and/or in the biological object (8) and/or capturing data using digital holographic microinterferometry (DHMI). The biological object (8) is characterized according to a result of the measurement and is sorted if needed. The stimulus can be applied by means of a laser beam that creates optical tweezers or an optical trap, by means of ultrasonic waves or an electric or magnetic radio frequency field.

Therapeutic methods and medicines may be developed by identifying a gene responsible for progressive supranuclear palsy, as may effective therapeutic methods and medicines. A medicine for progressive supranuclear palsy may contain a compound for inhibiting the expression of a filamin-A gene is provided. Also provided is an assessment system that uses cells expressing filamin-A, which is used in the search for medicaments for progressive supranuclear palsy or their candidates.

The disclosure discloses an in-vivo continuous directed evolution system and application thereof, and belongs to the fields of gene engineering and enzyme engineering. The system includes Escherichia coli host bacteria carrying a random mutation module mutagenesis plasmid, a programmed death module toxin-antitoxin system and a target gene expression module target plasmid. The modules are coupled with one another, and target genes are subjected to multiple rounds of continuous mutation by virtue of the random mutation module mutagenesis plasmid in the system, so that the mutation rate of the target genes is further increased, and ultimately, efficient evolution and screening of the target genes in the host bacteria are realized. According to the system, mutations are accurately positioned on the target genes, random mutations in non-target gene regions are reduced, and the system has good practical value and can be applied to directed evolution of various different functional proteins.

This invention provides compounds, compositions and methods for modulating the expression of human GST-π using RNA interference. The RNA interference molecules can be used in methods for preventing or treating diseases such as malignant tumor. Provided are a range of siRNA structures, having one or more of nucleotides being modified or chemically-modified. Advantageous structures include siRNAs with 2′-deoxy nucleotides located in the seed region, as well as other nucleotide modifications.

This invention provides compounds, compositions and methods for modulating the expression of human GST-π using RNA interference. The RNA interference molecules can be used in methods for preventing or treating diseases such as malignant tumor. Provided are a range of siRNA structures, having one or more of nucleotides being modified or chemically-modified. Advantageous structures include siRNAs with 2′-deoxy nucleotides located in the seed region, as well as other nucleotide modifications.

A method for screening substances for their ability to reduce malodours from emanations from an animal, said method comprising determining the effect of said substances on the C-S lyase activity of bacteria that emit volatile sulphuric compounds (VSCs), by contacting a test substance with a sample comprising said bacteria or a supernatant obtainable from a culture of said bacteria in the presence of a substrate for a C-S lyase, detecting the levels of thiol production from said bacteria, and comparing the results with those obtained from similar bacteria in the absence of said substance.

A system and method for analyzing bodily fluid include a sample holder holding a bodily fluid sample, an image capture device generating an image of the bodily fluid sample comprising a plurality of fields of view. An image processor is programmed to determine a biofilm in the bodily fluid sample from the image, determine a biofilm area or volume within each of the plurality of fields of view to form a plurality of biofilm areas, determine a total biofilm area or total biofilm volume by adding the plurality of biofilm areas, determine a first value corresponding to a comparison of the total biofilm area or the total biofilm volume and a total volume of the bodily fluid sample, and classify the first value into a classification. An analyzer, using the classification, displays an indicator on a display for indicating the classification of the biofilm within the bodily fluid sample.

The present disclosure provides modified bacteria and modified peptidoglycan comprising modified D-amino acids; compositions comprising the modified bacteria or peptidoglycan; and methods of using the modified bacteria or peptidoglycan. The modified D-amino acids include a bioorthogonal functional group such as an azide, an alkyne or a norbornene group. Also provided are modified peptidoglycans conjugated to a molecule of interest via a linker.